Infliximab (anti-TNF-alpha)

目录号：A2019         批次号: A201901

打印

Infliximab (anti-TNF-alpha)是一种纯化的重组DNA衍生的嵌合人-鼠IgG单克隆抗体，由小鼠重链和轻链可变区与人重链和轻链恒定区组成。Infliximab 通过与可溶性和跨膜形式的TNF-α高亲和力结合而中和 TNF-α 的生物学活性，并抑制或阻止TNF-α与受体的有效结合。MW=144.2 kDa。

抗体信息

CAS号 170277-31-3
配制 PBS, pH 7.0 Contains no stabilizers or preservatives
推荐同型对照 Chimeric IgG1
来源 Chimeric (mouse/human)
储存条件
(自收到货起)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
除菌 0.2 μM filtered
纯度 97.9%
蛋白浓度 5.00mg/ml
内毒素 <1EU/mg

Infliximab (anti-TNF-alpha)在文献中得到引用

Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies [ Cancer Commun (Lond), 2024, 44(3):408-432] PubMed: 38407943
Modeling and therapeutic targeting of inflammation-induced hepatic insulin resistance using human iPSC-derived hepatocytes and macrophages [ Nat Commun, 2023, 14(1):3902] PubMed: 37400454
Modeling and therapeutic targeting of inflammation-induced hepatic insulin resistance using human iPSC-derived hepatocytes and macrophages [ Nat Commun, 2023, 14(1):3902] PubMed: 37400454
Human iPSC-Derived Proinflammatory Macrophages cause Insulin Resistance in an Isogenic White Adipose Tissue Microphysiological System [ Small, 2023, 19(34):e2203725] PubMed: 37104853
Human iPSC-Derived Proinflammatory Macrophages cause Insulin Resistance in an Isogenic White Adipose Tissue Microphysiological System [ Small, 2023, e2203725.] PubMed: 37104853
c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma [ Front Immunol, 2022, 13:854995] PubMed: 35359966

禁止用于人体及治疗！